NCT Number: NCT04703920
Phase: Phase 1
Trial Summary: This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic B – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym:
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives